Quick Answer
Foghorn Therapeutics Inc. reported Total Revenue of $30.91 million for fiscal year 2025.
Foghorn Therapeutics Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $30.91M | +36.8% |
| 2024 | $22.60M | -33.8% |
| 2023 | $34.16M | +77.6% |
| 2022 | $19.23M | +1357.8% |
| 2021 | $1.32M | +206.7% |
| 2020 | $430.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.15M | +4.4% | +7.9% |
| June 30, 2025 | $7.56M | +9.7% | +27.0% |
| March 31, 2025 | $5.95M | +17.9% | -23.8% |
| September 30, 2024 | $7.81M | -55.3% | +13.4% |
| June 30, 2024 | $6.89M | +23.0% | +36.4% |
| March 31, 2024 | $5.05M | -4.9% | -71.1% |
| September 30, 2023 | $17.48M | +163.5% | +212.2% |
| June 30, 2023 | $5.60M | +24.7% | +5.5% |
- Foghorn Therapeutics Inc. showed an increase of +36.8% in Total Revenue compared to the prior fiscal year.
- Over the 2020–2025 period, Foghorn Therapeutics Inc.’s total revenue has grown by 7088.1% (from $430.0 thousand to $30.91 million).
- The most recent figure is from Foghorn Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: